The latest trading session saw Hims & Hers Health, Inc. (HIMS) ending at $37.04, denoting a -0.99% adjustment from its last day's close. This change lagged the S&P 500's daily gain of 0.16%. At the ...

Health care companies slid as traders retreated from high-risk issues. Shares of obesity-drug maker Novo Nordisk and Hims & Hers Health, the compounding pharmacy seeking to compete with the ...

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a ...

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

A skincare startup got bought for $190 million—then shut down. Here's what entrepreneurs can learn from the rise and fall of ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Hims & Hers Health. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...

Learn more about whether Alignment Healthcare, Inc. or Hims & Hers Health, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Hims & Hers Health, Inc. or LifeStance Health Group, Inc. is a better investment based on AAII's A+ ...